UNSPSC 51294416: Aripiprazole cavoxil

This classification denotes an antipsychotic agent C30H39Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SE284EQRL, chemically known as (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2h)-yl)methyl hexanoate, but more generally known as aripiprazole cavoxil, which bears US NIH Compound Identifier 49831462. Most nations, for tariff and trade purposes, schedule aripiprazole cavoxil under HS 29337900 and SITC 51561.

As of Q4 2014, ARIPIPRAZOLE CAVOXIL remains US FDA's Preferred Term for this commodity. SMILES: CCCCCC(=O)OCN1C2CC(CCC2CCC1=O)OCCCCN3CCN(CC3)C4CCCC(C4CL)CL.

UNSPSC 51294416 Aripiprazole cavoxil is a Commodity code nominally for a single pharmaceutical active ingredient, but recent state and local solicitations tagged under this code show little alignment with that specific drug. Instead, the recent opportunities span naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products — a divergence suggesting either broad mis-tagging or a code that functions as a catch-all for general pharmaceutical purchasing. The work actually being solicited includes naloxone and drug deactivation systems for community health initiatives, therapeutic pharmacy program design and market research, and cooperative purchasing arrangements for generic medications and OTC products distributed across multiple state and local health facilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing organizations spanning multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance).

Recent opportunities show geographic spread across Florida, Texas, and the multi-state region served by MMCAP (Minnesota, Oregon, and participating jurisdictions). The Seminole County, Florida IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year contract term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring vendor capabilities for a direct-to-manufacturer prescription program to serve state employee health plans outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for manufacturers to supply generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract awards effective July 1, 2026, and a two-year initial term. This code shows limited recent activity clearly matching its stated pharmaceutical commodity scope.